Replimune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. 

CEO
Sushil Patel
CEOSushil Patel
Employees
465
Employees465
Headquarters
Woburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded
2015
Founded2015
Employees
465
Employees465

REPL Key Statistics

Market cap
1.38B
Market cap1.38B
Price-Earnings ratio
-4.28
Price-Earnings ratio-4.28
Dividend yield
Dividend yield
Average volume
5.02M
Average volume5.02M
High today
$14.65
High today$14.65
Low today
$13.81
Low today$13.81
Open price
$13.86
Open price$13.86
Volume
295.95K
Volume295.95K
52 Week high
$15.71
52 Week high$15.71
52 Week low
$1.50
52 Week low$1.50

Stock Snapshot

With a market cap of 1.38B, Replimune(REPL) trades at $14.59. The stock has a price-to-earnings ratio of -4.28.

During the trading session on 2026-08-21, Replimune(REPL) shares reached a daily high of $14.65 and a low of $13.81. At a current price of $14.59, the stock is +5.6% higher than the low and still -0.4% under the high.

Trading volume for Replimune(REPL) stock has reached 295.95K, versus its average volume of 5.02M.

Over the past 52 weeks, Replimune(REPL) stock has traded between a high of $15.71 and a low of $1.50.

Over the past 52 weeks, Replimune(REPL) stock has traded between a high of $15.71 and a low of $1.50.

REPL News

TipRanks 1d
Replimune Insider Move Sparks Fresh Debate on Investor Strategy

New insider activity at Replimune Group ( (REPL) ) has taken place on August 19, 2026. Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with...

Investing.com 2d
Replimune CFO Emily Hill sells $132,175 in stock for tax obligations - Investing.com

...

Replimune CFO Emily Hill sells $132,175 in stock for tax obligations - Investing.com
TipRanks 3d
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop

Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that investors were not told key facts about regulatory weaknesses in the c...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

More REPL News

Simply Wall St 4d
Is Replimune Group Fully Valued Following FDA Approval Of TUDRIQEV?

Replimune Group (REPL) drew fresh attention after the FDA granted accelerated approval for TUDRIQEV in combination with nivolumab in advanced cutaneous melanoma...

Is Replimune Group Fully Valued Following FDA Approval Of TUDRIQEV?

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.